Journal of Scientific Papers

ECONOMICS & SOCIOLOGY


© CSR, 2008-2019
ISSN 2071-789X

3.1
2019CiteScore
 
91th percentile
Powered by  Scopus



Directory of Open Access Journals (DOAJ)


Strike Plagiarism

Partners
  • General Founder and Publisher:

     
    Centre of Sociological Research

     

  • Publishing Partners:

    University of Szczecin (Poland)

    Széchenyi István University, (Hungary)

    Mykolas Romeris University (Lithuania)

    Alexander Dubcek University of Trencín (Slovak Republic)


  • Membership:


    American Sociological Association


    European Sociological Association


    World Economics Association (WEA)

     


    CrossRef

     


MANAGING PUBLIC HEALTHCARE UNITS IN POLAND – RESEARCH FINDINGS

Vol. 4, No 1a, 2011

 

 

 

 HEALTH TECHNOLOGY ASSESSMENT – IS IT THE WAY TO SEARCH FOR COST – EFFECTIVE MEDICINES IN CENTRAL AND EASTERN EUROPE?

 Marcin Czech

 

Abstract. Health Technology Assessment (HTA) is a multidisciplinary process that summarizes information about medical, social, economic and ethical issues related to the use of a health technology in a systematic, transparent, unbiased, robust manner. HTA constitutes an integral part of a decision making process covering, among others, pricing and reimbursement of drugs and medical devices in Central and Eastern Europe.

In this review I describe the main definitions and elements of HTA placed in a context of healthcare systems’ reforms with a special emphasis on budget control tools in the Region. I also give information on some model solutions, brief history, main limitations, challenges and conditions of further development of the domain, together with some discussion from the pharmaceutical industry’s perspective.

 

Keywords:Health Technology Assessment, HTA, Pharmacoeconomics, Central and Eastern Europe, Evidence – Based Medicine.

 

JEL Classification: I180.


References

1. Auray J-P., Beresniak A., Claveranne J-P., Duru D.: Dictionnaire commente d’economie de la sante Masson, Paris 1996.

2. Bootman, J.L., Townsend, R.J. McGhan, W.F.: Principles of Pharmacoeconomics. 2nd edition, New York, 1996, Harvey Whitney Book Company.

3. Carlson JJ, Garrison LP Jr, Sullivan SD. Paying for outcomes: innovative coverage and reimbursement schemes for pharmaceuticals. JManag Care Pharm 2009 Oct; 15 (8): 683-7.

4.National Institute for Health and Clinical Excellence Web Page http://www.nice.org.uk/aboutnice/whoweare

/structureofnice/structure_of_nice.jsp accessed 05.2010

5. Kristensen F.B.: EUnetHTA and health policy-making in Europe. Eurohealth 2006, 12(1), 36-38.

6. Moher D, Tetzlaff J, Tricco AC, Sampson M, Altman DG (2007). "Epidemiology and reporting characteristics of systematic reviews". PLoS Med. 4 (3).


Marcin Czech, MD, Associate Professor

Department of Pharmacoeconomics

Faculty of Pharmacy

Medical University of Warsaw

Poland

marcin.czech@wum.edu.pl